摘要
目的比较普瑞巴林和加巴喷丁对糖尿病周围神经痛的疗效及安全性。方法将60例糖尿病周围神经痛患者按随机数字表法分为普瑞巴林组（30例）和加巴喷丁组（30例），分别给予普瑞巴林和加巴喷丁治疗4周。用视觉模拟量表（VAS）评分进行临床疗效评定，观察不良反应的发生情况。结果普瑞巴林组和加巴喷丁组治疗后1、2、4周末VAS评分[（4．05±0．93）、（2．73±0．72）、（2．06±0．58）分和（5．42±0．88）、（2．934±0．80）、（2．194±0．64）分]均较治疗前[（7．454±0．82）分和（7．684±0．84）分]显著下降（P〈0．01），治疗后1周末普瑞巴林组VAS评分较加巴喷丁组显著下降（P〈0．01），两组治疗后2、4周末VAS评分比较差异无统计学意义（P〉0．05）。两组治疗后4周末有效率比较差异无统计学意义（P〉0．05）。普瑞巴林组不良反应发生率[16．67％％（5／30）]明显低于加巴喷丁组[36．67％（11／30）]（P〈0．01）。结论普瑞巴林与加巴喷丁治疗糖尿病周围神经痛疗效相当，但起效更快，不良反应更小。
Objective To compare the efficacy and safety of pregabalin and gabapentin in treatment of patients with diabetic peripheral neuropathic pain. Methods Sixty patients with diabetic peripheral neuropathic pain were allocated into pregabalin group （30 cases） and gabapentin group （30 cases） for a 4-week period treatment by random digits table method. The efficacy was measured with visual analogue scale （VAS） score,while the side effects were evaluated. Results VAS score in both groups was significantly lower at the end of 1 st, 2nd or 4th week after treatment than that before treatment [ pregabalin group ： （4.05 ± 0.93）, （2.73 ±0.72）, （2.06 ±0.58） scores vs. （7.45 ±0.82） scores; gabapentin group： （5.42 ±0.88）, （2.93 ± 0.80）, （2.19 ± 0.64） scores vs. （7.68 ± 0.84） scores] （P 〈 0.01 ）. VAS score in pregabalin group was lower than that in gabapentin group at the end of 1st week significantly （P〈 0.01 ）. Not only there was no significant difference in VAS score at the end of 2nd or 4th week between two groups, but also in response rates at the end of 4th week （P 〉 0.05 ）. The rate of adverse reaction in pregabalin group was significantly lower than that in gabapentin group [ 16.67% （5/30） vs. 36.67% （ 11/30） ] （ P 〈 0.01 ）. Conclusion Pregabalin is as effective as gabapentin in treatment of patients with diabetic peripheral neuropathic pain, but it has faster effect and less adverse events than gabapentin.
出处
《中国医师进修杂志》
2012年第25期29-31,共3页
Chinese Journal of Postgraduates of Medicine
